New Delivery Option for Ketamine

Video

How can new formulations of ketamine impact patient care?

Jeffrey Becker, MD, discusses new formulations of ketamine for subcutaneous delivery and how ketamine works.

Dr Becker is cofounder and Chief Scientific Officer at Bexson Biomedical, Inc.

Related Videos
“What we’re striving to do is conquer the unmet needs that are still here with treating ADHD, especially from a medication standpoint.”
Work takes up one-third of a patient’s life—it is important that we pay attention to it.
A new treatment in development is poised to be a game-changer for patients with postpartum depression.
An expert discusses the latest on EndeavorRx and more digital therapeutics for this patient population.
Related Content
An expert discusses the common causes of burnout, as well as what both organizations and clinicians can do to support clinician well-being.

4 Questions About Burnout

January 31st 2024
Article
“If approved, KarXT would represent a new mechanism of action to treat schizophrenia, which would be the first new mechanism potentially in decades.”

Changing the Way Schizophrenia Is Treated

January 5th 2024
Article
Here’s what the historic case of the Genain quadruplets reveals about some deeper, uncomfortable truths about American society.

Girls and Their Monsters, Part 3

September 18th 2023
Article
An expert discusses recent research evaluating a selective M4 positive allosteric modulator for the treatment of schizophrenia.

EMPOWERing the Next Generation

September 13th 2023
Article
Exploring the connection between trauma and the etiology of schizophrenia, and the ways this connection was historically interpreted in the case of the Genain quadruplets.

Girls and Their Monsters, Part 2

September 7th 2023
Article
How is sailing similar to treating mood disorders?

The Joy of Sailing

September 4th 2023
Article
© 2024 MJH Life Sciences

All rights reserved.